Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-mini-CHOP is a combination chemotherapy regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (or prednisone). It is a modified version of the standard R-CHOP protocol with reduced doses of each component. The regimen was specifically developed for elderly patients (typically over 80 years old) or those with significant comorbidities who are ineligible for full-dose chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on R-mini-CHOP.